ArticleCancer research2017
Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 78 citations in OpenAlex.
- The multifaceted roles of tumor-infiltrating plasma cells in cancer immunology.Fundamental research · 2026Review
- AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- Elucidating the relationship between affinity and potency in the performance of therapeutic IgE.Scientific reports · 2026Article
- Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice.International journal of biological sciences · 2026Review
- Low serum IgE is associated with an increased risk of chronic lymphocytic leukemia: a large retrospective cohort study.Frontiers in immunology · 2026Observational
- Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality.mAbs · 2025Article
- Article
- Review
- Article
- IgE based therapeutics are an emerging modality in cancer treatment.Discover oncology · 2025Review
- Article
- Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction.Nature communications · 2025Article
- Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors.Journal for immunotherapy of cancer · 2025Article
- Association of immunoglobulin E levels with glioma risk and survival.Journal of the National Cancer Institute · 2025Article
- An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities.Journal of experimental & clinical cancer research : CR · 2025Article
- Immune Boosters and Immunotherapy in Allergic Diseases and in Cancer Management.Archives of Razi Institute · 2025Review
- Current status and future prospects of cancer-derived immunoglobulins in pancreatic cancer.Journal of Cancer · 2025Review
- Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision Therapies.International journal of molecular sciences · 2024Article
- Association of immunoglobulin E levels with glioma risk and survival.medRxiv : the preprint server for health sciences · 2024Article
- Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 10 institutions in 5 countries.
Debra H JosephsSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Heather J BaxSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Tihomir DodevNIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London, London, United Kingdom.
Mirella GeorgouliTumor Plasticity Laboratory, Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom.
Mano NakamuraSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Giulia PellizzariSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Louise SaulSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Panagiotis KaragiannisSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Anthony CheungSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Cecilia HerraizTumor Plasticity Laboratory, Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom.
Kristina M IlievaSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Isabel CorreaSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Matthew FittallSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Silvia CrescioliSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Patrycja GazinskaKing's Health Partners Cancer Biobank, Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Natalie WoodmanKing's Health Partners Cancer Biobank, Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Silvia MeleSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Giulia ChiaruttiniSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Amy E GilbertSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Alexander KoersDivision of Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom.
Marguerite BracherRandall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom.
Christopher SelkirkBiotherapeutics Development Unit, Cancer Research UK, South Mimms, Hertfordshire, United Kingdom.
Heike LentferBiotherapeutics Development Unit, Cancer Research UK, South Mimms, Hertfordshire, United Kingdom.
Claire BartonCentre for Drug Development, Cancer Research UK, London, United Kingdom.
Elliott LeverSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Gareth MuirheadDepartment of Informatics, Faculty of Natural and Mathematical Sciences, King's College London, London, United Kingdom.
Sophia TsokaDepartment of Informatics, Faculty of Natural and Mathematical Sciences, King's College London, London, United Kingdom.
Silvana CanevariMolecular Therapies Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione, IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy.
Mariangela FiginiMolecular Therapies Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione, IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy.
Ana MontesDepartment of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Noel DownesSequani, Ledbury, Herefordshire, United Kingdom.
David DombrowiczInstitut National de la Santé et de la Recherche Médicale U1011, Lille, France.
Christopher J CorriganDivision of Asthma, Allergy and Lung Biology, MRC and Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, London, United Kingdom.
Andrew J BeavilNIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London, London, United Kingdom.
Frank O NestleSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Paul S JonesCentre for Drug Development, Cancer Research UK, London, United Kingdom.
Hannah J GouldNIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London, London, United Kingdom.
Victoria Sanz-MorenoTumor Plasticity Laboratory, Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom.
Philip J BlowerDivision of Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom.
James F SpicerDivision of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Sophia N KaragiannisSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom. sophia.karagiannis@kcl.ac.uk.
King's College London · GBSt Thomas' Hospital · GBCancer Research UK · GBFondazione IRCCS Istituto Nazionale dei Tumori · ITLondon Cancer · GBUniversity of Hertfordshire · GBAsthma UK · GBGuy's and St Thomas' NHS Foundation Trust · GBHereford Health and Safety Group · GBInstitut National de Recherche en Santé Publique · ML
Funding
Cancer Research UK 11060Cancer Research UK 12065Cancer Research UK 15774Cancer Research UK 16463Cancer Research UK 18887Cancer Research UK 24478Medical Research Council G1000758Medical Research Council G1100090Medical Research Council MR/L023091/1
Abstract
IgE antibodies are key mediators of antiparasitic immune responses, but their potential for cancer treatment via antibody-dependent cell-mediated cytotoxicity (ADCC) has been little studied. Recently, tumor antigen-specific IgEs were reported to restrict cancer cell growth by engaging high-affinity Fc receptors on monocytes and macrophages; however, the underlying therapeutic mechanisms were undefined and
Indexed as
AnimalsAntibodies, Anti-IdiotypicCell Line, TumorFemaleFolate Receptor 1HumansMacrophagesOvarian NeoplasmsRatsRats, WistarSignal TransductionTumor Necrosis Factor-alphaAntibodies, Anti-Idiotypicanti-IgE antibodiesFolate Receptor 1TNF protein, humanTumor Necrosis Factor-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.